secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-021658
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron reports Q4/FY2023 results; cash $378M, PDUFA June 16, 2024 for imetelstat
-------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $378.1M as of Dec 31, 2023; cash runway into Q3 2025.
- FDA PDUFA action date June 16, 2024 for imetelstat NDA in transfusion-dependent LR-MDS; ODAC meeting March 14, 2024.
- Total operating expenses FY2023: $194.1M (R&D $125M, G&A $69.1M); FY2024 guidance $270-280M.
- Phase 3 IMpactMF for myelofibrosis achieved 50% enrollment; interim analysis expected H1 2025.
- Revenue minimal at $237,000 for FY2023; company plans to grow to ~270 employees by end of 2024 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/0000950170-24-021658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017024021658/gern-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer